It is difficult to achieve immunity to MV infection by use of vaccines in infants during the first 6-9 months of life because of the presence of maternal antibody. Morbidity and mortality due to MV infection would decrease substantially if a vaccine administered at birth could prime immunity in the presence of maternal antibody. We demonstrate here that an MV DNA vaccine administered to infant macaques in the presence of maternal antibody primes MV-specific T cell responses but not de novo neutralizing antibody. This vaccine protected 80% of the infant macaques from skin rash and MV-induced immunosuppression. A molecular interleukin-2 adjuvant was required for protection with this vaccine. This macaque model shows that infants can be vaccinated against MV in the presence of maternal antibody. These results suggest that it is possible to develop an MV DNA vaccine that could protect infants in developing countries during the first months of life.
Measles is the most contagious infection known, and vaccine coverage 195% is necessary to protect a population [1] . Developing countries are still burdened with high levels of infant morbidity and mortality caused by measles. The live attenuated vaccine is heat labile and requires a cold chain, which makes it difficult to store and administer in remote regions where conditions are harsh [2] . Infants with measles-specific maternal antibody have low rates of seroconversion after the administration of live attenuated vaccine [3] [4] [5] . Because of low vaccine coverage and the high susceptibility of infants to measles, developing countries have adopted programs to vaccinate infants at age 6-9 months. Vaccination at this age has resulted in seroconversion rates as low as 60% [6] , which is significantly below that of developed nations, where vaccination at age 12-15 months can yield 194% seroconversion [6] . It would therefore be beneficial to develop a vaccine capable of being administered at birth in the presence of maternal antibody. This vaccine would serve to protect infants from severe disease during their first year of life and, possibly, to reduce transmission of measles virus (MV), allowing for the administration of the live attenuated vaccine at a time when seroconversion rates could approach 95%. Recent evidence suggests that human infants are able to develop T cell immunity to the live attenuated MV vaccine, even in the presence of maternal antibody [7] .
DNA vaccines provide a novel mechanism to circumvent maternal antibody and have been shown to be effective at priming immunity in infants [8] [9] [10] [11] [12] [13] . When administered by the intradermal (id) route, the DNA transfects fibroblasts, keratinocytes, and dendritic cells [14] . Vaccine immunogens are then produced in vivo, processed, and presented to induce antigen-specific humoral and cellular immunity [14, 15] . Vaccination with MV DNA has been shown to be immunogenic and protective in juvenile macaques [16, 17] . In addition, an MV DNA vaccine consisting of the hemagglutinin (H), fusion (F), and nucleoprotein (N) genes, administered id at multiple sites, at a dose of 100 mg of DNA/plasmid, induced MV-specific immunity in infant rhesus macaques in the presence of maternal antibody [11] . In that study, the addition of an interleukin (IL)-2 molecular adjuvant 48 h after vaccination protected 90% of infant macaques from measles.
For an infant measles vaccine to be practical for use in developing countries, the dose and the route of administration must be convenient and practical. We hypothesized that a simplified measles vaccine administered id at 1 site with a syringe, a technique commonly used in developing countries, would prime MV-specific immunity and protect infants from disease, in the presence of maternal antibodies. Trials of human DNA vaccines for HIV and malaria have been conducted with 20-3000 mg of DNA [18, 19] . All doses were administered intramuscularly, and no adverse effects were detected. Doses of at least 100 mg induced virus-specific neutralizing antibody responses, and doses 1100 mg also induced cell-mediated immunity (CMI), priming both CD4 and CD8 T cells [19, 20] . We have demonstrated elsewhere that 300 mg of MV DNA with 100 mg of an IL-2 molecular adjuvant can prime infant macaques and protect against measles [11] .
In the present study, 3 measles plasmids encoding the measles H, F, and N genes were combined into a single 0.1-mL inoculum and administered id. Some macaques received an IL-2/IgG DNA adjuvant added to the inoculum (50 mg) or administered 48 h after vaccination. The infant macaques were boosted at age 2 months and were challenged at age 5 months. To test for MV-induced immunosuppression, as an index of protection against a major complication of measles [21] , at 1 week after challenge, the infant macaques received a tetanus vaccine. This DNA vaccination strategy induced MV-specific immune responses that protected 80% of infant macaques, when IL-2 was administered 48 h after vaccination, and 60% of infant macaques, when IL-2 was included in the inoculum. In addition, all infant macaques vaccinated against measles mounted antitetanus antibodies. Therefore, it is possible to vaccinate infant macaques against measles in the presence of maternal antibody and to protect them against disease and immunosuppression.
MATERIALS AND METHODS
Plasmid constructs. DNA plasmids were constructed as described elsewhere [11] . In brief, the pND plasmid used to express vaccine genes contains the cytomegalovirus immediateearly (IE) 1 promoter-enhancer region [22] , an IE1 intron, and the bovine growth hormone polyadenylation signal in a pUC19 backbone. Measles H, F, and N genes from the Edmonston strain were cloned as described elsewhere [23] . Control plasmids included the pND vector containing genes from influenza H and influenza NP (strain A/PR/8/32; provided by P. Palase, Mt. Sinai School of Medicine, New York, NY) and Escherichia coli b-galactosidase. The IL-2 molecular adjuvant was an IL-2/ IgG DNA plasmid provided by D. Barouch and N. Letvin (Harvard University, Boston, MA), expressing a recombinant human IL-2/IgG Fc fusion protein, as described elsewhere [24] . Endotoxin was measured by use of the limulus assay and was !3 U/mg of DNA.
Vaccination with MV. Colony-bred male and female infant rhesus macaques were housed in accordance with the guidelines of the Committee on Care and Use of Laboratory Animals of the National Resources Council. Infant macaques (1-2 days old; mean body weight, 0.5 kg) were administered 4.0 mL of measles immunoglobulin (MIG) or PBS subcutaneously (figure 1). MIG is a pool of heat-inactivated serum from macaques that contracted measles during an outbreak in the colony, as described elsewhere [25] . The reciprocal neutralizing antibody titer of MIG is 5120, as determined by 50% end-point titration. Forty-eight hours later, the infant macaques were administered a single id inoculation of MV DNA (150 mg of DNA/0.1 mL), consisting of measles H, F, and N genes (50 mg of DNA/plasmid). Control macaques received a similar injection of 3 control DNA plasmids. Some infant macaques received 50 mg of an IL-2/IgG molecular adjuvant in the vaccine inoculum; others received this adjuvant 48 h after vaccination (figure 1). All macaques were boosted with the same regimen at 2 months after vaccination.
Challenge with MV. At age 5 months, the macaques were challenged by intranasal inoculation with a standard dose of the Davis 87 isolate of MV grown in rhesus peripheral blood mononuclear cells (PBMCs) [26] . The macaques were monitored daily for anorexia, depression, coughing, diarrhea, and skin rash. Blood samples were obtained 7, 14, and 28 days after challenge. Virus loads were quantified as the TCID 50 in PBMCs by end-point dilution coculture with Raji cells, as described elsewhere [27] . PBMCs were prepared from heparinized venous blood by use of density centrifugation, as described elsewhere [27] .
Vaccination with tetanus toxoid. One week after challenge with MV, all macaques were vaccinated with tetanus toxoid (20 mL/kg of body weight subcutaneously; unconcentrated Tetanus Toxoid; Colorado Serum Company). Tetanus antibody titers were determined at 21 and 96 days after vaccination. All macaques were boosted with tetanus toxoid at 4 months after challenge with MV, and blood samples were obtained 2 weeks after the boost. Titers of antibody in serum were measured by use of ELISA, using purified tetanus toxoid (Accurate Chemical and Scientific) and positive/negative control rhesus serum, as described elsewhere [28] .
Neutralizing antibody assay. As described elsewhere [27] , neutralizing antibodies were measured by use of viral antigen reduction in Vero cells in 96-well plates. The serum neutralizing titer is reported as the highest dilution showing a 50% reduction in viral antigen.
CMI. MV-specific CMI was measured by use of an interferon (IFN)-g ELISPOT assay, as described elsewhere [11] . In brief, PBMCs were resuspended in a 48-well flat-bottom plate ( cells/mL) in AIM-V medium (Gibco) supplemented 6 5 ϫ 10 with 10% fetal calf serum and stimulated overnight with live MV, Edmonston strain (1000 TCID 50 /100 mL; American Type Culture Collection). Positive control stimuli were 10 ng/mL PMA (Sigma Chemical) and 1 mg/mL ionomyocin (Sigma). After incubation overnight, the cells were transferred to a 96-well ELISPOT plate coated with antibody to rhesus IFN-g (UCytech BV) (2-cells/well for both medium control and 5 5 ϫ 10 MV-stimulated wells and cells/well for PMA/ionomyo-4 1 ϫ 10 cin wells). Spots were developed according to the manufacturer (U-Cytech BV). Spot-forming cells were counted under a dissecting microscope, and the numbers of spots in duplicate wells were averaged. A positive result was at least 10 spots/well and greater than or equal to the SD of the medium conmean + 2 trol. The number of spots in medium control wells was subtracted from the experimental spot count, and the number of spot-forming cells was adjusted to 10 6 PBMCs. Statistical analysis. Neutralizing antibody titers, viremia, and IFN-g-positive spot-forming cells were considered to be dichotomous variables. Fisher's exact probability test was used to analyze the relationship between antibody status or CMI prechallenge and viremia. Differences in postchallenge peak virus loads among macaques that were or were not given IL-2 were analyzed by use of the Kruskal-Wallis 1-way analysis of variance (ANOVA) by ranks. Post hoc testing was performed by use of Dunne's multiple comparison test. The relationship between postchallenge virus load and response to vaccination with tetanus toxoid was analyzed by use of Fisher's exact probability test.
RESULTS

Experimental design.
In keeping with a previous study design [11] , all infant macaques were administered MIG or PBS at birth, vaccinated 48 h later, boosted at age 2 months, and challenged at age 5 months, as shown in figure 1. To test for MV-induced immunosuppression as a pathologic consequence of MV infection, at 1 week after challenge, all infant macaques received a tetanus toxoid vaccine. The infant macaques were randomly assigned to the control DNA or experimental groups. All of the infant macaques assigned to the control DNA group received PBS, and the infant macaques assigned to the MV DNA vaccine groups were pretreated with MIG. A major experimental variable was the use of the IL-2/IgG plasmid as an adjuvant. In earlier studies of mice, this adjuvant was more effective if administered at 48 h after DNA vaccination rather than at the time of vaccination [29] . In our previous MV vaccine study of infant macaques, the IL-2 adjuvant was effective when administered 48 h after vaccination [11] . In the present study, we tested the efficacy of the IL-2 adjuvant when injected at the time of vaccination, which was more practical than injecting it 48 h after vaccination.
Challenge with MV and disease. At 5 months after initial vaccination, the macaques were challenged by the intranasal route with MV Davis 87 [26] . As shown in figure 2A , viremia in the control group peaked on day 7 and was undetectable at 4 weeks after challenge, as described elsewhere [11] . In addition, skin rashes were observed on all the control macaques (table 1). The MV DNA-vaccinated infant macaques, with or without the IL-2 adjuvant, were significantly protected against measles, compared with control macaques ( , ANOVA). How-P p .0087 ever, only 1 of 5 macaques vaccinated with MV DNA in the absence of IL-2 had no detectable viremia or disease (figure 2B and table 1). Three macaques that received the MV DNA vaccine with IL-2/IgG at the time of vaccination had no detectable viremia or disease ( figure 2C and table 1) , and 4 macaques given the MV DNA vaccine with the IL-2/IgG adjuvant 48 h after vaccination had no detectable viremia or disease ( figure  2D and table 1) . Overall, 7 of 10 macaques given the MV DNA vaccine with the IL-2 adjuvant were protected against measles, but only 1 of 5 macaques vaccinated without the IL-2 adjuvant was protected.
Humoral immunity. On the day of vaccination, all infant macaques in the control DNA group, which received PBS, had protective titers (у80) of maternal antibody (table 2) , and the infant macaques in the MV DNA groups, which received MIG, also had protective titers (table 2). These antibodies waned over time, and, by week 20, only 2 macaques had neutralizing antibody titers у80 (table 2). There was no significant difference in antibody responses in macaques that received the measles DNA vaccine with or without IL-2 ( , Fisher's exact test). P p 1.0 After challenge with MV, 4 control macaques had neutralizing antibody titers у80 at 2 weeks, but not at 1 week, after challenge (table 2), as predicted for an MV-naive macaque [25] . Two of 5 macaques administered the measles DNA vaccine without IL-2 had an anemnestic response at 1 week after challenge (3-fold increase in titer; table 2). In addition, 6 of 10 macaques that received the measles DNA vaccine with IL-2 had an antibody response 1 week after challenge (table 2) . Macaques 34233 and 34221 had no measles antibody responses to vaccination or challenge (table 2), up to 4 weeks after challenge (data not shown).
CMI. MV-specific T cells that produce IFN-g were tested at the following time points: week 8 (day of boost), week 10 (2 weeks after boost), week 20 (day of challenge), and weeks 21-22 (after challenge). No control infant macaque had detectable CMI before challenge (table 2). Two of 5 infant macaques that received the MV DNA vaccine without the IL-2 adjuvant had detectable CMI at 2 weeks after boost (у20 sfcs/ 10 6 PBMCs; table 3). On the day of boost, 2 of 5 infant macaques that received MV DNA together with IL-2 had detectable CMI, as did 2 of 5 macaques that received the MV DNA vaccine with IL-2 administered at 48 h (table 3) . At week 10, 3 of 5 macaques that received MV DNA together with IL-2 had detectable CMI, as did 4 of 5 infant macaques that received the MV DNA vaccine with IL-2 administered at 48 h later. By week 20, a CMI response to MV was undetectable in all vaccinated macaques (table 2) . This result differs from that in our previously reported experiment with 300 mg of MV DNA injected at multiple sites [11] , in which most vaccinated infant macaques had detectable CMI at week 20 (day of challenge). At 1 and 2 weeks after challenge, CMI was detected in 4 of 5 control macaques and in 10 of 15 MV-vaccinated macaques. The pattern of CMI response after challenge is puzzling and does not reveal a difference between control and vaccinated macaques. We speculate that this may be due, in part, to repeated, multiple exposures to MV after challenge, because all of the infant macaques were housed in open cages in the same room. Overall, MV-specific IFN-g-positive spot-forming cells were detected NOTE. Data are spot-forming cells (sfcs)/10 6 peripheral blood mononuclear cells (PBMCs). After stimulation in vitro with MV, interferon-g-positive sfcs were counted by use of an ELISPOT assay, and their frequencies were calculated as sfcs/10 6 PBMCs. After subtraction of medium control sfcs, a positive response was considered to be у20 sfcs/10 6 PBMCs, as indicated in bold type. IL-2, interleukin-2; ND, not determined.
in most infant macaques vaccinated in the presence of MIG, but there was no significant difference in pre-or postchallenge CMI when IL-2 was included in the inoculum.
Response to vaccination with tetanus toxoid. On day 7 after challenge with MV, when the infants had peak virus loads (figure 2), they received a tetanus toxoid vaccine to determine whether they could mount an antibody response to an unrelated antigen. All macaques that were protected against viremia and disease were able to mount antitetanus antibody responses, and, in marked contrast, most macaques that had high-level viremia and skin rash did not mount a humoral response to tetanus toxoid (table 1) . Macaques 34239 and 34252, which were able to control their infection at 2 weeks after challenge, also responded to vaccination with tetanus toxoid. There were 2 exceptions to the phenomenon of virus-induced immunosuppression, control macaque 34258 and experimental macaque 34238, which had high-level viremia and skin rash but were able to respond to vaccination with tetanus toxoid. However, there was a significant negative correlation between protection from measles and immunosuppression ( , Fisher's ex-P p .0256 act test). After a booster vaccination with tetanus toxoid, all macaques except 34241 had anemnestic antibody responses, with end-point titers ranging from 1:2000 to 1:800,000 (data not shown). Thus, the failure to respond to vaccination with tetanus toxoid during challenge with MV was likely not due to an underlying immunodeficiency in these macaques.
DISCUSSION
This relatively simple prime/boost DNA vaccination strategy was able to prime the infant macaques' immune system, in the presence of maternal antibody, for protection against MV infection. When IL-2 was included in the inoculum, 60% of infants were protected against disease, and 80% were protected against immunosuppression. When IL-2 was administered 48 h after vaccination, 80% of infants were protected against measles and immunosuppression. In addition, of 7 infant macaques vaccinated with MV DNA that had skin rash and viremia, 3 were able to mount antitetanus antibody responses (table 1) and were therefore protected against immunosuppression.
These results confirm those obtained when this DNA vaccine was administered at multiple sites, at a dose of 100 mg of DNA/ plasmid [11] . In the present study, the infant macaques' antibody responses were lower than in the previous study, possibly because the dose of DNA was lower (50 mg), and inclusion of the plasmid encoding IL-2 at 0 or 48 h did not significantly augment them. There was, however, a significant reduction in viremia and skin rash, compared with control macaques, when IL-2 was administered with the DNA vaccine ( , 1-P p .0056 way ANOVA). Although neutralizing antibody titers on the day of challenge were at or below a protective level in the present study, there was a rapid, anamnestic antibody response after challenge with MV in 8 of 15 of the vaccinated infant macaques (at week 21 [1 week after challenge]; table 2), suggesting that B cells and/or CD4 + T cells had been primed by vaccination. Of course, we cannot rule out a possible effect of maternal antibody at the time of initial vaccination in promoting a cellular response [30] . The priming of a T cell response in the presence of maternal antibody has recently been observed in human infants vaccinated against measles and mumps [7] .
Understanding the correlates of immunity is important in a vaccine model. In the case of human measles, it is known that neutralizing antibody plays a key role in preventing infection and that CMI is also necessary for protection against severe disease and viral clearance. In the present study, immunity to the measles DNA vaccine favored a cellular response (table 3), in that 60% of the macaques had detectable CMI, whereas only 13% had antibody responses before challenge. In T cell depletion experiments, the MV-specific IFN-g-positive spot-forming cells that we detected were CD8 + , but we could not exclude the contribution of CD4 + T cells in some macaques (data not shown). Although no difference was seen in prechallenge CMI when IL-2 was administered in the present study and in the previous multiple-injection-site study [11] , this adjuvant significantly increased protection from disease (P p .0008, Fisher's exact test). The immune mechanism triggered by the IL-2/IgG molecular adjuvant in this infant macaque vaccine model is not clear. However, in juvenile macaques, a single intramuscular injection of this IL-2/IgG plasmid resulted in transient, low-level increases in peripheral blood CD4 + T cells [31] . We have not measured MV-specific CD4 + T cells in response to DNA vaccination in infant macaques. The detection of MVspecific, cytokine-positive CD4 + and CD8 + T cells by flow cytometry will be a useful index of primary vaccine immunity in this infant macaque vaccine model [7] .
Even though a mechanism of protection has not been fully characterized, the results of the present study clearly show that an adjuvant is required for successful vaccination of infant macaques with an MV DNA vaccine. The adjuvant requirement could be due to the immaturity of the infant primate's immune system or to a general observation that DNA vaccines are weaker immunogens in primates than in mice [14] . When this MV DNA vaccine was administered to immunocompetent juvenile macaques, by use of the same prime/boost regimen as that used with the infant macaques but without the IL-2/IgG adjuvant, all vaccinated macaques had detectable CMI and neutralizing antibody before challenge, but only 50% of the macaques were protected against high-level viremia [32] , suggesting that this MV DNA vaccine is a weak immunogen rather than that the infant primate is immunodeficient. In fact, the record of success for vaccines in human infants belies the notion that infant immunity is significantly deficient. Human infants vaccinated at birth with bacille Calmette-Guèrin (BCG), a live attenuated vaccine, mount effective T cell responses against tuberculosis [33] . When vaccinated with the live attenuated MV vaccine at age 6 months, human infants had CMI equivalent to that of 1-year-olds, in the presence or absence of maternal antibody, although the 6-month-old infants had lower neutralizing antibody titers than did the older infants [7, 34] .
When juvenile macaques were vaccinated with MV DNA plus the IL-2/IgG adjuvant, MV-specific immunity was induced, and anamnestic responses occurred after inoculation with the live attenuated MV vaccine 5 months later [32] . This result suggests that primary vaccination with MV DNA at birth may not interfere with the subsequent administration of a first dose of standard, live attenuated MV vaccine to 9-12-month-old infants. Therefore, an MV DNA vaccine could be used to greatly reduce the morbidity and mortality associated with measles in developing countries [35] and allow for administration of the live attenuated MV vaccine at an age when optimal seroconversion would be achieved.
Vaccination with DNA is able to circumvent the effect of maternal antibody and prime immunity in infants against measles, but this will require a practical adjuvant, since IL-2 is not currently approved as an adjuvant in humans and is not likely to be used in HIV-exposed infants in developing countries. Nor is the optimal timing of IL-2 injection practical, at 48 h after vaccination. A practical alternative would be BCG vaccine, which has demonstrable adjuvant effects [36] . BCG is approved for administration to infants, and its use and coverage in developing countries is high. In addition, BCG has been shown to induce a Th1 response in human infants [33] and to augment immunity to coadministered poliovirus and hepatitis B virus vaccines [36] . If an MV DNA vaccine administered at birth with BCG provides protection against measles without preventing the later use of the live attenuated MV vaccine, it would be a practical strategy for protecting infants from measles during the first months of life.
